Ong Khaa Hoo, Hsieh Yao-Yu, Sun Ding-Ping, Huang Steven Kuan-Hua, Tian Yu-Feng, Chou Chia-Lin, Shiue Yow-Ling, Joseph Keva, Chang I-Wei
Division of Gastroenterology & General Surgery, Department of Surgery, Chi Mei Medical Center, Tainan 710, Taiwan.
Department of Medical Technology, Chung Hwa University of Medical Technology, Tainan 717, Taiwan.
Diagnostics (Basel). 2023 Jul 6;13(13):2296. doi: 10.3390/diagnostics13132296.
Intrahepatic cholangiocarcinoma (IHCC) is the second most common malignant neoplasm of the liver. In spite of the increasing incidence worldwide, it is relatively rare in Western countries. IHCC is relatively common in Eastern and Southeastern Asia. Patients with IHCC are usually diagnosed at an advanced stage, therefore, the clinical outcome is dismal. Dysregulation of urea cycle metabolic enzyme expression is found in different types of cancers. Nevertheless, a comprehensive evaluation of genes related to the urea cycle (i.e., GO:0000050) has not been conducted in IHCC. By performing a comparative analysis of gene expression profiles, we specifically examined genes associated with the urea cycle (GO:0000050) in a publicly accessible transcriptomic dataset (GSE26566). Interestingly, was identified as the second most prominently down-regulated gene in this context. Tumor tissues of 182 IHCC patients who underwent curative-intent hepatectomy were enrolled. The expression level of CPS1 protein in our IHCC cohort was assessed by immunohistochemical study. Subsequent to that, statistical analyses were carried out to examine the expression of CPS1 in relation to various clinicopathological factors, as well as to assess its impact on survival outcomes. We noticed that lower immunoreactivity of CPS1 in IHCC was associated with tumor progression (pT status) with statistical significance ( = 0.003). CPS1 underexpression was not only negatively correlated to overall survival (OS), disease-specific survival (DSS), local recurrence-free survival (LRFS) and metastasis-free survival (MeFS) in univariate analysis but also an independent prognosticator to forecast poorer clinical outcome for all prognostic indices (OS, DSS, LRFS and MeFs) in patients with IHCC (all ≤ 0.001). These results support that CPS1 may play a crucial role in IHCC oncogenesis and tumor progression and serve as a novel prognostic factor and a potential diagnostic and theranostic biomarker.
肝内胆管癌(IHCC)是肝脏第二常见的恶性肿瘤。尽管其在全球的发病率不断上升,但在西方国家相对罕见。IHCC在东亚和东南亚地区相对常见。IHCC患者通常在晚期被诊断出来,因此临床预后较差。在不同类型的癌症中都发现了尿素循环代谢酶表达的失调。然而,尚未对IHCC中与尿素循环相关的基因(即GO:0000050)进行全面评估。通过对基因表达谱进行比较分析,我们在一个可公开获取的转录组数据集(GSE26566)中专门研究了与尿素循环(GO:0000050)相关的基因。有趣的是,在这种情况下, 被确定为第二显著下调的基因。纳入了182例行根治性肝切除术的IHCC患者的肿瘤组织。通过免疫组织化学研究评估了我们的IHCC队列中CPS1蛋白的表达水平。在此之后,进行了统计分析,以检查CPS1的表达与各种临床病理因素的关系,并评估其对生存结果的影响。我们注意到,IHCC中CPS1的免疫反应性较低与肿瘤进展(pT状态)相关,具有统计学意义( = 0.003)。在单变量分析中,CPS1低表达不仅与总生存期(OS)、疾病特异性生存期(DSS)、无局部复发生存期(LRFS)和无转移生存期(MeFS)呈负相关,而且是预测IHCC患者所有预后指标(OS、DSS、LRFS和MeFs)临床结果较差的独立预后因素(所有 ≤ 0.001)。这些结果支持CPS1可能在IHCC的肿瘤发生和肿瘤进展中起关键作用,并可作为一种新的预后因素以及潜在的诊断和治疗诊断生物标志物。